Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
InnoCare Pharma Limited (INCPF)
Beijing, CN
InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination with MIL-62. Furthermore, Orelabrutinib is under investigation for a range of autoimmune conditions such as systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company's broader pipeline features several investigational candidates in various clinical trial stages. For example, ICP-192, a pan-FGFR inhibitor, is currently in Phase I/II trials for solid tumors like cholangiocarcinoma and head and neck cancer. Compounds in Phase I clinical trials include ICP-723, a pan-TRK inhibitor addressing cancers with neurotrophic tyrosine receptor kinase fusions; ICP-332, a novel tyrosine kinase 2 (TYK2) inhibitor for autoimmune diseases; and ICP-B02, a bispecific antibody targeting lymphoma. Further preclinical and early-stage assets encompass ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver, renal cell, colorectal, and other solid tumors; ICP-488 for autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for various cancers; and ICP-248 and ICP-490, both focusing on hematological conditions, with ICP-490 also extending to autoimmune diseases. Additionally, InnoCare offers Tafasitamab (marketed as ICP-B04), indicated for the treatment of diffuse large B-cell lymphoma and other hematological malignancies. Established in 2015, InnoCare Pharma Limited maintains its headquarters in Beijing, China.
Based on only 1 article — low confidence
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -27.23% | -24.39% | -52.45% | -52.45% | -58.11% | -58.11% | -58.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+127.6% ★ Q1'26: +37.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+238.5% ★ Q1'26: +492.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-8.3% Q1'26: -0.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+19.2% ★ Q1'26: +12.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+21.4% ★ Q1'26: +12.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.2% Q1'26: -1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.90× ★ Q1'26: 6.72× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 1 EPS Ana. |
Dec 2027 10 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.36M
est: 12.57M (-89.2%)
|
1.04B
est: 1.01B (+2.9%)
|
625.40M
est: 604.94M (+3.4%)
|
738.54M
est: 732.55M (+0.8%)
|
1.01B
est: 986.43M (+2.3%)
|
2.30B
est: 2.08B (+10.7%)
|
2.31B
2.05B – 2.55B
+11.4% YoY
|
2.91B
2.60B – 3.27B
+26.0% YoY
|
3.68B
3.27B – 4.10B
+26.2% YoY
|
| EBITDA |
-556.92M
est: -7.97M (-6,888.7%)
|
-167.20M
est: -642.64M (+74.0%)
|
-808.28M
est: -383.45M (-110.8%)
|
-516.55M
est: -464.34M (-11.2%)
|
-312.55M
est: -380.25M (+17.8%)
|
555.93M
est: -799.99M (+169.5%)
|
-891.08M
-984.29M – -788.34M
-11.4% YoY
|
-1.12B
-1.26B – -1.00B
-26.0% YoY
|
-1.42B
-1.58B – -1.26B
-26.2% YoY
|
| EBIT |
-558.99M
est: -8.59M (-6,410.6%)
|
-182.53M
est: -692.39M (+73.6%)
|
-876.68M
est: -413.14M (-112.2%)
|
-609.18M
est: -500.29M (-21.8%)
|
-418.81M
est: -438.56M (+4.5%)
|
440.63M
est: -922.66M (+147.8%)
|
-1.03B
-1.14B – -909.23M
-11.4% YoY
|
-1.29B
-1.46B – -1.15B
-26.0% YoY
|
-1.63B
-1.82B – -1.45B
-26.2% YoY
|
| Net Income |
-391.40M
est: -792.92M (+50.6%)
|
-64.55M
est: 6.76M (-1,054.2%)
|
-886.59M
est: -840.45M (-5.5%)
|
-631.26M
est: -760.34M (+17.0%)
|
-440.63M
est: -509.79M (+13.6%)
|
625.89M
est: 243.35M (+157.2%)
|
164.68M
140.77M – 189.38M
-32.3% YoY
|
214.17M
183.09M – 246.30M
+30.1% YoY
|
476.84M
407.62M – 548.35M
+122.6% YoY
|
| SGA |
113.15M
est: 213.50M (-47.0%)
|
344.66M
est: 17.22B (-98.0%)
|
613.27M
est: 10.27B (-94.0%)
|
252.13M
est: 12.44B (-98.0%)
|
310.64M
est: 448.43M (-30.7%)
|
718.73M
est: 943.42M (-23.8%)
|
1.05B
929.68M – 1.16B
+11.4% YoY
|
1.32B
1.18B – 1.49B
+26.0% YoY
|
1.67B
1.48B – 1.86B
+26.2% YoY
|
| EPS |
-0.40
est: -0.47 (+14.7%)
|
-0.04
est: 0.00 (-1,014.9%)
|
-0.60
est: -0.50 (-20.7%)
|
-0.37
est: -0.45 (+17.7%)
|
-0.26
est: -0.29 (+10.1%)
|
0.36
est: 0.14 (+160.7%)
|
0.09
0.08 – 0.11
-32.3% YoY
|
0.12
0.10 – 0.14
+30.1% YoY
|
0.27
0.23 – 0.31
+122.6% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jisong Cui | Co-Founder, Chairwoman & Chief Executive Officer | 1M | — |
| Renbin Zhao | Senior Vice President of Clinical Development & Medical Research and Executive Director | 503.5K | — |
| John Zhou | C.M.O | — | — |
| Junjian Liu | Senior Vice President of Biology & Biologics | — | — |
| Junsu Wang | General Counsel | — | female |
| Nan Gao | Chief Operating Officer | — | male |
| Xiangyang Chen | Chief Technology Officer | — | — |
| Xin Fu | Chief Financial Officer | — | male |
| Davy Ouyang | Vice President & Head of Biology | — | male |
| Yue Tan | Accounting Supervisor | — | — |
| Jeff Chen | Chief Commercial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INCPF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
